New Antibody Drug Slashes Dangerous Cholesterol by 59% in Genetic Disorder
SHR-1918 antibody dramatically reduced LDL cholesterol in patients with severe genetic hypercholesterolemia through novel pathway.
Summary
A new antibody drug called SHR-1918 reduced dangerous LDL cholesterol by 59% in patients with homozygous familial hypercholesterolemia, a rare genetic disorder causing extremely high cholesterol from birth. Unlike traditional cholesterol medications that rely on liver receptors, this treatment works through a completely different pathway by targeting the ANGPTL3 protein. In a 12-week study of 26 patients, the monthly injection consistently lowered cholesterol levels across different genetic variants of the condition. The treatment was generally well-tolerated, with mild side effects like temporary protein in urine. This breakthrough offers hope for people with severe genetic cholesterol disorders who don't respond well to standard treatments.
Detailed Summary
Homozygous familial hypercholesterolemia (HoFH) is a devastating genetic condition affecting cholesterol metabolism, causing life-threatening cardiovascular disease from childhood. Patients have extremely high LDL cholesterol because their liver receptors can't properly clear cholesterol from blood, making traditional medications largely ineffective.
Researchers tested SHR-1918, a monoclonal antibody targeting ANGPTL3 protein, which regulates cholesterol through a pathway independent of liver receptors. This 12-week study included 26 Chinese adults with HoFH who received monthly 600mg injections while continuing their existing cholesterol medications.
Results were remarkable: LDL cholesterol dropped by an average of 59% from baseline levels of 434 mg/dL. The reduction was consistent across different genetic variants and persisted throughout an 8-week follow-up period. Notably, the treatment worked equally well regardless of specific genetic mutations causing the condition.
For longevity and cardiovascular health, this represents a paradigm shift in treating severe cholesterol disorders. High LDL cholesterol accelerates atherosclerosis and premature death, so dramatic reductions could significantly extend lifespan in affected individuals. The LDLR-independent mechanism may also benefit people with other forms of treatment-resistant hypercholesterolemia.
However, this was a small, single-arm study without a control group, conducted only in Chinese patients. Long-term safety and efficacy data are needed, and the treatment's availability and cost remain unclear. While promising for rare genetic conditions, broader applications for cholesterol management require further investigation.
Key Findings
- SHR-1918 reduced LDL cholesterol by 59% in patients with severe genetic hypercholesterolemia
- Treatment worked through novel ANGPTL3-targeting pathway independent of traditional liver receptors
- Monthly injections maintained cholesterol reduction throughout 12-week treatment and 8-week follow-up
- Effectiveness was consistent across different genetic variants of the condition
- Side effects were mild, with proteinuria being most common at 15.4% of patients
Methodology
Single-arm, non-randomized phase 2 trial with 26 adults with homozygous familial hypercholesterolemia. Patients received monthly 600mg subcutaneous injections for 12 weeks followed by 8-week observation period.
Study Limitations
Small sample size, no control group, short duration, and conducted only in Chinese population. Long-term safety, efficacy, and broader applicability require additional studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.